Dr. Katy Kai-Ju Tsai, MD

Dr. Tsai practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Tsai's NPI, 1417275827, was assigned on May 10, 2010. Dr. Tsai graduated from The Warren Alpert Medical School of Brown University in 2010. Dr. Tsai holds California license A124908.

Dr. Tsai's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Tsai's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. Dr. Tsai is also affiliated with UCSF Langley Porter Psychiatric Hospital. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Tsai to 3 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tsai practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Tsai's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dmand AI has Dr. Tsai's licenses on file in 2 states: California and North Carolina.

CMS data shows 523 Medicare services from Dr. Tsai across 4 procedure codes in 2024, for 170 Medicare patients. Medicare paid $49,715 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 170 Medicare patients who saw Dr. Tsai in 2024. The largest group is 65 to 74, with 84 patients. 69% of them have high cholesterol, and 68% have high blood pressure. 15% are also on Medicaid. Their average risk score is 2.21, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tsai's median patient age at 71, with 46% women.

In 2024, Dr. Tsai wrote 69 Medicare Part D claims for 25 patients. 62% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $98 in total drug cost. In 2021, CMS named 14 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Tsai for performance year 2024, reported as part of a group. Dr. Tsai accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tsai as offering telehealth.

Dmand AI links 20 papers to Dr. Tsai, published from 2015 to 2024. 2021 was the busiest year, with 3. The most frequent topics are Melanoma, Immunotherapy and Antineoplastic Agents. Dr. Tsai has published most often in Cancer. Dr. Tsai's most frequent co-authors are Adil I. Daud, MD, Alain Algazi, MD and Harish Vasudevan, MD, PhD.

Dmand AI links Dr. Tsai to 1 clinical trial. Conditions studied include Cholangiocarcinoma and Thyroid Neoplasms.

CMS Open Payments shows 30 general payments to Dr. Tsai from 8 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 71% of the total. Bristol-Myers Squibb Company paid the most, $10,072. It also lists 5 research payments totaling $5,740 from 2021 to 2023.

Dr. Tsai graduated from The Warren Alpert Medical School of Brown University in 2010.

Dr. Tsai is in network with 7 carriers, including Blue Cross Blue Shield of Michigan, Elevance and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.